Entrada Therapeutics, Inc.TRDANASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
|
|
|
|

Operating cash flow minus capital expenditures

Latest
$-44.72M
↓ 163% below average
Average (5y)
$-16.99M
Historical baseline
Range
High:$134.19M
Low:$-96.67M
CAGR
+31.4%
Consistent expansion
PeriodValueChange
2024$-44.72M-133.3%
2023$134.19M+238.8%
2022$-96.67M-74.4%
2021$-55.44M-98.8%
2020$-27.89M-144.0%
2019$-11.43M-